InflaRx Yönetim

Yönetim kriter kontrolleri 2/4

InflaRx CEO'su Niels Riedemann, Jan2007 tarihinde atandı, in görev süresi 17.83 yıldır. şirketin hisselerinin 1.82% doğrudan sahiptir ve bu hisselerin değeri $ 2.22M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.5 yıldır.

Anahtar bilgiler

Niels Riedemann

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	17.8yrs
CEO sahipliği	1.8%
Yönetim ortalama görev süresi	3.9yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (51 yo)

17.8yrs

Görev süresi

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niels Riedemann	Co-Founder	17.8yrs	Veri yok	1.82% $ 2.2m
Renfeng Guo	Co-Founder	17.8yrs	Veri yok	2.99% $ 3.7m
Thomas Taapken	Chief Financial Officer	4.1yrs	Veri yok	0.0059% $ 7.3k
Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	1.6yrs	Veri yok	Veri yok
Camilla Chong	Chief Medical Officer	1.3yrs	Veri yok	Veri yok
Jan Medina	Head of Investor Relations & VP	less than a year	Veri yok	Veri yok
Christian Schmid	VP and Head of Legal Affairs & General Counsel	no data	Veri yok	Veri yok
Nicole Bertsch	Senior Director & Head of Human Resources	3.7yrs	Veri yok	Veri yok
Maria Habel	VP, Head of Preclinical R&D and QC	11.8yrs	Veri yok	Veri yok
Bruce Burnett	VP & Head of Medical Affairs	no data	Veri yok	Veri yok
Kofi Boaten	Senior Director and Head of Supply Quality & Clinical Trial Supplies	no data	Veri yok	Veri yok
Peter Hurt	Senior Director and Head of Drug Safety & Pharmacovigiliance	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: IFRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niels Riedemann	Co-Founder	no data	Veri yok	1.82% $ 2.2m
Renfeng Guo	Co-Founder	no data	Veri yok	2.99% $ 3.7m
Nicolas Fulpius	Independent Chairman of the Board	17.8yrs	Veri yok	0.79% $ 973.3k
K. Reinhart	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
P. Ward	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Brudnick	Independent Non-Executive Director	5.5yrs	Veri yok	0.085% $ 104.0k
Hege Hellstrom	Non-Executive Director	1.6yrs	Veri yok	Veri yok
Mark Kubler	Independent Non-Executive Director	9.8yrs	Veri yok	1.63% $ 2.0m
Anthony Gibney	Independent Non-Executive Director	3.5yrs	Veri yok	0.017% $ 20.8k

5.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IFRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

InflaRx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

InflaRx N.V., Annual General Meeting, Apr 25, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Co-Founder notifies of intention to sell stock

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates fall by 72%

New major risk - Financial position

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

Consensus EPS estimates upgraded to €0.69 loss

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Consensus revenue estimates fall by 13%

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

No longer forecast to breakeven

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 68%

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Consensus revenue estimates increase by 883%, EPS downgraded

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Consensus revenue estimates increase by 34%

Consensus revenue estimates increase by 34%

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx reports Q2 results

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Consensus revenue estimates fall by 31%

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Our First Look At InflaRx

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Consensus forecasts updated

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab